Multivariate analysis of risk factors
| Parameter . | hemEFS . | OS . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| Higher age | 0.90 | 0.63-1.28 | .55 | 0.65 | 0.37-1.15 | .14 |
| Translocation t(11;14) positive | 0.52 | 0.31-0.88 | .014 | 0.56 | 0.27-1.20 | .14 |
| Gain of 1q21 positive | 1.18 | 0.63-2.21 | .61 | 0.59 | 0.23-1.54 | .28 |
| Light chain (λ vs κ) | 1.54 | 0.77-3.09 | .22 | 2.79 | 0.89-8.75 | .08 |
| Higher dFLC | 1.96 | 1.27-3.03 | .002 | 3.43 | 1.58-7.47 | .002 |
| Mayo score (II/III vs I)* | 0.84 | 0.49-1.43 | .51 | 1.82 | 0.80-4.15 | .15 |
| Lower MDRD | 1.28 | 0.95-1.72 | .11 | 1.10 | 0.77-1.57 | .60 |
| Effectively reduced melphalan dosage† | 4.97 | 2.00-12.38 | <.001 | 2.21 | 0.72-6.79 | .17 |
| Parameter . | hemEFS . | OS . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| Higher age | 0.90 | 0.63-1.28 | .55 | 0.65 | 0.37-1.15 | .14 |
| Translocation t(11;14) positive | 0.52 | 0.31-0.88 | .014 | 0.56 | 0.27-1.20 | .14 |
| Gain of 1q21 positive | 1.18 | 0.63-2.21 | .61 | 0.59 | 0.23-1.54 | .28 |
| Light chain (λ vs κ) | 1.54 | 0.77-3.09 | .22 | 2.79 | 0.89-8.75 | .08 |
| Higher dFLC | 1.96 | 1.27-3.03 | .002 | 3.43 | 1.58-7.47 | .002 |
| Mayo score (II/III vs I)* | 0.84 | 0.49-1.43 | .51 | 1.82 | 0.80-4.15 | .15 |
| Lower MDRD | 1.28 | 0.95-1.72 | .11 | 1.10 | 0.77-1.57 | .60 |
| Effectively reduced melphalan dosage† | 4.97 | 2.00-12.38 | <.001 | 2.21 | 0.72-6.79 | .17 |
Hazard ratios (HRs) are based on unit changes for categorical variables, on 10-year change for age, and on change of interquartile range for other continuous variables. Log-transformed values were used for dFLC. Induction therapy (no vs yes) was used as a stratifying variable. Statistically significant results (P < .05) are in bold.
In patients with heart transplant before high-dose chemotherapy, the Mayo score is set at I by definition to account for the improved cardiac situation.
Effectively reduced melphalan dosage refers to melphalan dose reductions as a result of age or severity of organ involvement (n = 7), but not to melphalan dose adjustments according to renal function only.